Breaking News from Macao, China

from Bing and Google News
China , Wednesday 15 April 2026

Zai Lab Announces Approval to Commercialize ZEJULA (Niraparib) in Macau for Patients with Relapsed Ovarian Cancer

Published on: Wednesday 12 June 2019

Zai Lab in-licensed rights to ZEJULA from Tesaro, which was recently acquired by GlaxoSmithKline, for China, Hong Kong and Macau as an important, new treatment option for patients who suffer from ...


News source: https://www.marketwatch.com/press-release/zai-lab-announces-approval-to-commercialize-zejula-niraparib-in-macau-for-patients-with-relapsed-ovarian-cancer-2019-06-12-91842415

Share this news on:  

RELATED NEWS

» Macau schools to raise Chinese national flag, state media says
» Next China: The Mood on the Street
» Zai Lab Announces Approval to Commercialize ZEJULA (Niraparib) in Macau for Patients with Relapsed Ovarian Cancer
» China, Hong Kong homebuyers play cross-border musical chairs in Bay Area

HEADLINE NEWS